Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Divine Skin enters Brazil

Executive Summary

Miami Beach-based biotech firm launches its first Latin American subsidiary - DS Laboratories do Brasil Ltd. - complete with local office, resident pharmacist and sales force in place. "This is a major milestone in the meteoric growth of Divine Skin worldwide," says Daniel Khesin, founder and chief executive, adding: "We expect Brazilian sales to be visible in 2010 figures and to contribute strongly in 2011 and beyond." Firm's flagship DS Laboratories brand expects its Nia radiant color shampoo and conditioner and Nirena pH-balanced feminine cleanser to roll out first in Brazil, as they are considered Level-1 cosmetics of minimal risk, Divine Skin indicates in its Oct. 4 release. The company's Oligo.DX cellulite-reducing gel is concluding 60-day efficiency testing, required of Level-2 cosmetics in Brazil, and has demonstrated an "astounding" 90% success rate, according to the firm. Efficiency tests for Divine Skin's Revita hair-growth-stimulating shampoo should wrap by the end of October, and tests for the rest of the DS Laboratories line should be finished by the year's end, Divine Skin notes. Firm cites Brazil's gross domestic product of $2 tril. and population growth rate of 1.2% annually. Divine Skin launched a dedicated consumer health division in July (1"The Rose Sheet" July 12, 2010)
Advertisement

Related Content

Divine Skin Launches Consumer Health Division
Divine Skin Launches Consumer Health Division
Advertisement
UsernamePublicRestriction

Register

RS017254

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel